

Gary L Rosner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/270976/publications.pdf>

Version: 2024-02-01

24
papers

3,158
citations

516215

16
h-index

642321

23
g-index

24
all docs

24
docs citations

24
times ranked

6010
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
2	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 1553-1561.	0.8	430
3	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	0.6	259
4	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 3817-3827.	0.6	165
5	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	1.7	152
6	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. <i>Science Translational Medicine</i> , 2015, 7, 288ra78.	5.8	104
7	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2017, 1, 288-292.	2.5	84
8	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1099-1102.	2.0	61
9	Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. <i>Cancer</i> , 2018, 124, 1904-1911.	2.0	59
10	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 2037-2048.	0.8	51
11	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	3.2	50
12	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , 2018, 24, 6160-6167.	3.2	46
13	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 61, 108-116.	0.4	41
14	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1022-1028.	2.0	29
15	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	0.8	28
16	Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. <i>Clinical Trials</i> , 2016, 13, 621-631.	0.7	27
17	Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 695-706.	1.1	19
18	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 121-129.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials. <i>Frontiers in Medicine</i> , 2019, 6, 122.	1.2	13
20	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021, 13, 25.	1.8	11
21	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	3.2	6
22	Information Visualization Platform for Postmarket Surveillance Decision Support. <i>Drug Safety</i> , 2020, 43, 905-915.	1.4	6
23	Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy). <i>Blood</i> , 2014, 124, 730-730.	0.6	5
24	Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan. <i>Biometrics</i> , 2020, 76, 599-601.	0.8	0